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Previews
hydrogen bond between the 1-hydroxyl group of vitaminAugmenting Vitamin D to Combat
D and opens a hydrophobic “hole” adjacent to the li-Genetic Disease gand. Potential candidate compounds were designed
to fill this hydrophobic hole based on modified struc-
tures of vitamin D and the synthetic agonist L190155
Vitamin D-resistant rickets is a genetic disease that (see figure). Hydrophobic groups appended to these
causes severe bone underdevelopment due to muta- compounds were envisioned to confer additional hy-
tions in the vitamin D receptor. Orthogonal analogs of drophobic interactions within the ligand binding pocket
vitamin D were recently identified that correct defects and enable binding and proper activation of this defec-
in the ligand binding pocket of a mutant receptor asso- tive receptor. These compounds were subjected to a
ciated with this disease. virtual screen against the VDR R274L mutant model us-
ing Monte Carlo docking simulations to identify those
Vitamin D is a small molecule hormone that regulates compound candidates with the highest predicted asso-
numerous physiological processes, including calcium ciation energies. Using this rational design approach in
and phosphate absorption and bone development, by conjunction with small focused libraries of compounds,
binding to membrane-associated and nuclear vitamin D the Koh laboratory synthesized and evaluated vitamin
receptors (VDRs). The nuclear VDRs control gene ex- D analogs derived from 1,25(OH)2D3 and L190155.
pression by heterodimerizing with retinoid X receptors The rational design strategy employed by the Koh
(RXR). Vitamin D promotes this protein-protein interac- laboratory successfully identified novel compounds that
tion and initiates a complex series of molecular events, activate the R274L mutant VDR with up to 500-fold
including recognition of specific DNA sites by the recep- greater potency than existing VDR agonists. Impor-
tor complex, recruitment of coactivator proteins to DNA, tantly, these compounds were selective for this nuclear
and regulation of gene expression involved in the prolif- VDR and did not stimulate the activity of a VDR that
eration and differentiation of bone-forming osteoblast acts at the cellular plasma membrane. Compounds that
cells. Insufficient vitamin D results in rickets, a disease rescue only the defective nuclear VDR and do not acti-
characterized by softening and weakening of bones. vate the membrane VDR were desired because this
Although most cases of rickets can be prevented or membrane receptor is responsible for rapid and diverse
treated with vitamin D or related VDR agonists, individu- nongenomic effects of vitamin D [14]. Moreover, aber-
rant activation of signaling pathways controlled by theals with the genetic disease vitamin-D-resistant rickets
membrane VDR is thought to preclude the clinical use(VDRR) do not respond to this treatment. Patients with
of high doses of 1,25(OH)2D3 as a treatment for VDRR.this rare but devastating genetic disease experience
In contrast to the natural hormone, analogs of vitaminsevere bone underdevelopment. This is a result of muta-
D were previously suggested as potential therapeuticstions within the VDR, some of which directly block bind-
for VDRR by Dr. Sara Peleg of the M.D. Anderson Cancering of vitamin D to its receptor.
Center, who investigated a 1,25(OH)2D3 derivative bear-Previous work by a number of laboratories has pro-
ing a hydroxymethyl substituent in place of the morevided a chemical genetic strategy for complementing
polar 1-hydroxyl group. The Peleg laboratory reportedthese types of mutations using synthetic small mole-
that this vitamin D analog at least partially rescued acti-cules [1, 2]. This strategy has roots in the field of genet-
vation of gene expression by the defective R274L VDRics, where protein functions lost by mutation can often
mutant [15].be rescued by compensatory mutations (also known as
The results of Koh and coworkers provide additionalsecond-site revertants) [3]. The related chemical genetic
evidence at the molecular level that certain genetic dis-approach can be employed to identify synthetic ligands
eases might be corrected with appropriately designedthat are complementary to mutant proteins and rescue
small molecules. These results suggest that individualsloss-of-function mutations. This approach has enabled
with VDRR could be profiled by genetic screening tothe identification of orthogonal ligands complementary
identify mutations capable of complementation by smallto numerous mutant proteins, including the immunophi-
molecules. Although the number of potential candidateslins [4, 5], estrogen receptors [6–8], RXR [9], p53 [10],
will be limited by the large number of mutations knownand protein kinases [1].
to cause VDRR and the low frequency of mutations thatProfessor John Koh and his group at the University
form direct contacts with vitamin D (2 out of 20 knownof Delaware recently reported [11, 12] a chemical genetic
mutations [16]), this general rational design approachapproach for the treatment of VDRR. Using the X-ray
holds promise for the rapid identification of potent leadcrystal structure of the VDR bound to the biologically
compounds that rescue functions of specific mutantactive vitamin D metabolite 1,25(OH)2D3 [13], the Koh
members of the nuclear hormone receptor superfamily.laboratory constructed a computational model of a key
arginine to leucine (R274L) mutant known to cause
VDRR by directly interfering with vitamin D binding. The Blake R. Peterson
energy of this hydrophobic leucine side chain in the Department of Chemistry
ligand binding pocket of the model receptor was mini- The Pennsylvania State University
mized with a conformational search algorithm. Modeling 152 Davey Lab
University Park, Pennsylvania 16802indicated that this mutation results in loss of a critical
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Natural and Nonnatural Vitamin Ds Compared
with the Protein-Bound Vitamin
Structures of the active vitamin D metabolite
1,25(OH)2D3 (A), the related synthetic agonist
LG190155 (B), and the 1,25(OH)2D3-VDR com-
plex (C). In (C), the VDR arginine residue
(Arg274) known to be mutated to a smaller
hydrophobic leucine residue in cases of vita-
min D-resistant rickets and the proximal
1-hydroxyl group (1-OH) of 1,25(OH)2D3 modi-
fied to compensate for this mutation are ex-
plicitly shown.
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vances in gene manipulation have allowed researchers
to conduct more elegant experiments to dissect these
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Control in the N-linked Glycoprotein
Biosynthesis Pathway processes at the molecular level, and ultimately lend
support to the hypotheses generated by Lennarz’s ear-
lier work. Marth and colleagues strived to disrupt the
key glycosyltransferase genes using homologous re-N-linked glycosylation is vital for the development and
combination in mouse, and in this way showed thatmaintenance of eukaryotic cells. The individual steps
deletion of these genes resulted in embryonic lethality;of this complex process are slowly being elucidated.
interestingly, the earlier in the pathway the gene is de-In this issue, the Imperiali group further dissects the
leted, the less progressive the embryonic development.mechanics of oligosaccharyl transferase using sub-
Specifically, in this study, Marth and coworkers demon-strate analogs.
strated that disrupting the gene that encodes for the
dolichol GlcNAc-1-phosphotransferase (see figure), theThe glycosylation of proteins requires a significant com-
enzyme inhibited by tunicamycin, blocks mouse devel-mitment of genetic and energetic resources by eukary-
opment at gastrulation, precisely as Lennarz had shownotic cells. Since this complex process was discovered,
earlier in sea urchins [2, 3]. By contrast, mouse embryosresearchers have been trying to uncover and understand
that were homozygous for a disrupted gene encodingthe various steps and molecular mechanisms of glyco-
the protein N-acetylglucosylaminyltransferase I, an en-sylation that nature accomplishes with apparent ease.
zyme that acts at a later stage in the glycosylation path-The critical importance of N-linked (or asparagine-
way for the synthesis of complex N-linked oligosaccha-linked) glycosylation to multicellular organization was
rides, progress through the initial developmental events,demonstrated several years ago by Lennarz, who treated
but stop abruptly at embryonic stage E9.5–E10.5 [4, 5].sea urchin embryos with tunicamycin to completely ab-
Intervening in the early steps in the dolichol lipid path-late N-linked glycosylation and observed the cessation
of embryonic development [1]. Since that time, ad- way for N-linked glycosylation by either chemical or
